{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T13:20:32Z","timestamp":1787750432218,"version":"build-2784847793"},"reference-count":23,"publisher":"Ovid Technologies (Wolters Kluwer Health)","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"abstract":"<jats:sec>\n                    <jats:title>Objectives:<\/jats:title>\n                    <jats:p>Over the past 2 decades, adjuvant radiation therapy (RT) for early-stage breast cancer has shifted toward shorter regimens. While initially occurring over 5 to 6 weeks, level 1 evidence has supported the equivalence of 3 to 4 weeks of adjuvant RT. More recently, level 1 evidence has demonstrated equivalence of 1-week ultrahypofractionated RT (UHRT) to 3-week adjuvant RT. This study evaluates the adoption of UHRT in the United States before, during, and after the COVID-19 pandemic.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>Patients with early-stage breast cancer who received lumpectomy and adjuvant RT from 2018 to 2022 were assessed using the National Cancer Database (NCDB). UHRT was defined as 5.2\u00a0Gy per fraction with a total dose of 26\u00a0Gy. Data were grouped as prepandemic (2018 to 2019), pandemic (2020), and postpandemic (2021 to 2022). The adoption of UHRT and RT completion rates was assessed among these periods.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>\n                      Before, during, and after the pandemic, 0.98% (133\/13,154), 4.88% (303\/6208), and 14.27% of patients (2044\/14,321) underwent UHRT, respectively (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      &lt;0.0001). Cumulative RT completion rates were 94.85% before the pandemic, 96.10% during the pandemic, and 96.83% after the pandemic (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      &lt;0.0001), demonstrating a significant increase in adoption. For UHRT, completion rates were 100.00% prepandemic, 99.34% during the pandemic, and 99.46% postpandemic (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      =0.6651), higher than overall RT completion rates across all 3 periods.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion:<\/jats:title>\n                    <jats:p>Nationwide data demonstrates a 14-fold increase in the use of UHRT from 2018 to 2022. Despite this increase and the near 100% completion rates for UHRT, UHRT remains underutilized compared with standard and hypofractionated regimens. These findings indicate fertile ground for increased UHRT adoption in breast cancer care nationwide.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1097\/coc.0000000000001336","type":"journal-article","created":{"date-parts":[[2026,6,22]],"date-time":"2026-06-22T18:09:58Z","timestamp":1782151798000},"update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":0,"title":["Emergence of Single-Week Adjuvant Radiation Therapy for Early-Stage Breast Cancer in the United States"],"prefix":"10.1097","author":[{"given":"Nimisha","family":"Kasliwal","sequence":"first","affiliation":[{"name":"Department of Radiation Oncology"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie","family":"Gordon","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Evan","family":"Becker","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kai","family":"Ding","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shearwood","family":"McClelland","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology"},{"name":"Department of Neurological Surgery, University of Oklahoma Stephenson Cancer Center, University of Oklahoma College of Medicine, Oklahoma City, OK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2026,5,25]]},"reference":[{"key":"R1-20260622","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1097\/00000658-197205000-00002","article-title":"Modified radical mastectomy","volume":"175","author":"Madden","year":"1972","journal-title":"Ann Surg"},{"key":"R2-20260622","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1097\/00000658-190707000-00001","article-title":"The results of radical operations for the cure of carcinoma of the breast","volume":"46","author":"Halsted","year":"1907","journal-title":"Ann Surg"},{"key":"R3-20260622","doi-asserted-by":"crossref","first-page":"1233","DOI":"10.1056\/NEJMoa022152","article-title":"Twenty-year follow-up of a randomized trial comparing total mastectomy, lumpectomy, and lumpectomy plus irradiation for the treatment of invasive breast cancer","volume":"347","author":"Fisher","year":"2002","journal-title":"N Engl J Med"},{"key":"R4-20260622","doi-asserted-by":"crossref","first-page":"1558","DOI":"10.1200\/JCO.1996.14.5.1558","article-title":"Conservative treatment versus mastectomy in early breast cancer: patterns of failure with 15 years of follow-up data. Institut Gustave-Roussy Breast Cancer Group","volume":"14","author":"Arriagada","year":"1996","journal-title":"J Clin Oncol"},{"key":"R5-20260622","doi-asserted-by":"crossref","first-page":"1610378","DOI":"10.3389\/pore.2022.1610378","article-title":"Radiotherapy of breast cancer-professional guideline 1st Central-Eastern European Professional Consensus Statement on Breast Cancer","volume":"28","author":"Polg\u00e1r","year":"2022","journal-title":"Pathol Oncol Res"},{"key":"R6-20260622","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1016\/j.ijrobp.2014.09.030","article-title":"Predictors of radiation therapy noncompliance in an urban academic cancer center","volume":"91","author":"Ohri","year":"2015","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"R7-20260622","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1016\/j.ijrobp.2016.01.043","article-title":"Radiation therapy noncompliance and clinical outcomes in an urban academic cancer center","volume":"95","author":"Ohri","year":"2016","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"R8-20260622","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/j.breast.2006.11.003","article-title":"The impact of age and clinical factors on quality of life in early breast cancer: an analysis of 2208 women recruited to the UK START trial (Standardisation of Breast Radiotherapy Trial)","volume":"16","author":"Hopwood","year":"2007","journal-title":"Breast"},{"key":"R9-20260622","doi-asserted-by":"crossref","first-page":"e2200215","DOI":"10.1200\/GO.22.00215","article-title":"Benefits of adopting hypofractionated radiotherapy as a standard of care in low-and middle-income countries","volume":"8","author":"Kraus","year":"2022","journal-title":"JCO Glob Oncol"},{"key":"R10-20260622","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1016\/j.clbc.2020.06.006","article-title":"Predictors of whole breast radiation therapy completion in early stage breast cancer following lumpectomy","volume":"20","author":"McClelland","year":"2020","journal-title":"Clin Breast Cancer"},{"key":"R11-20260622","doi-asserted-by":"crossref","first-page":"1086","DOI":"10.1016\/S1470-2045(13)70386-3","article-title":"The UK Standardisation of Breast Radiotherapy (START) trials of radiotherapy hypofractionation for treatment of early breast cancer: 10-year follow-up results of two randomised controlled trials","volume":"14","author":"Haviland","year":"2013","journal-title":"Lancet Oncol"},{"key":"R12-20260622","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1056\/NEJMoa0906260","article-title":"Long-term results of hypofractionated radiation therapy for breast cancer","volume":"362","author":"Whelan","year":"2010","journal-title":"N Engl J Med"},{"key":"R13-20260622","doi-asserted-by":"crossref","first-page":"3261","DOI":"10.1200\/JCO.19.02750","article-title":"Ten-year results of FAST: a randomized controlled trial of 5-fraction whole-breast radiotherapy for early breast cancer","volume":"38","author":"Brunt","year":"2020","journal-title":"J Clin Oncol"},{"key":"R14-20260622","doi-asserted-by":"crossref","first-page":"1613","DOI":"10.1016\/S0140-6736(20)30932-6","article-title":"Hypofractionated breast radiotherapy for 1 week versus 3 weeks (FAST-Forward): 5-year efficacy and late normal tissue effects results from a multicentre, non-inferiority, randomised, phase 3 trial","volume":"395","author":"Murray Brunt","year":"2020","journal-title":"Lancet"},{"key":"R15-20260622","first-page":"e322","article-title":"Impact of COVID on utilization of ultra-hypofractionation in breast cancer treatment","volume":"120","author":"McDougall","year":"2024","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"R16-20260622","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1016\/j.clon.2020.03.006","article-title":"International guidelines on radiation therapy for breast cancer during the COVID-19 pandemic","volume":"32","author":"Coles","year":"2020","journal-title":"Clin Oncol (R Coll Radiol)"},{"key":"R17-20260622","first-page":"100807","article-title":"Implementation of ultra-hypofractionated radiotherapy schedules for breast cancer during the COVID-19 pandemic in the Netherlands","volume":"47","author":"Eijkelboom","year":"2024","journal-title":"Clin Transl Radiat Oncol"},{"key":"R18-20260622","doi-asserted-by":"crossref","first-page":"101668","DOI":"10.1016\/j.adro.2024.101668","article-title":"Ultrahypofractionated adjuvant breast radiation therapy (\u00b1 boost) and virtual consultations: patient perspectives at 1 year","volume":"10","author":"Nicholson","year":"2024","journal-title":"Adv Radiat Oncol"},{"key":"R19-20260622","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1016\/j.prro.2025.08.009","article-title":"Ultra-hypofractionated whole breast radiation therapy using a novel boost regimen for early-stage breast cancer","volume":"16","author":"Chakraborty","year":"2026","journal-title":"Pract Radiat Oncol"},{"key":"R20-20260622","doi-asserted-by":"crossref","first-page":"e333","DOI":"10.1016\/j.clon.2024.06.045","article-title":"Feasibility and safety of the \u201cone-week breast radiation therapy\u201d program","volume":"36","author":"Ba","year":"2024","journal-title":"Clin Oncol (R Coll Radiol)"},{"key":"R21-20260622","doi-asserted-by":"crossref","first-page":"e2400277","DOI":"10.1200\/GO-24-00277","article-title":"Phase II evaluation of ultra-hypofractionated postoperative radiation therapy for breast cancer: toxicity and efficacy in a single-center nonrandomized prospective study","volume":"11","author":"Fang","year":"2025","journal-title":"JCO Glob Oncol"},{"key":"R22-20260622","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1245\/s10434-007-9747-3","article-title":"The National Cancer Data Base: a powerful initiative to improve cancer care in the United States","volume":"15","author":"Bilimoria","year":"2008","journal-title":"Ann Surg Oncol"},{"key":"R23-20260622","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/jso.10320","article-title":"The National Cancer Data Base: a clinical surveillance and quality improvement tool","volume":"85","author":"Winchester","year":"2004","journal-title":"J Surg Oncol"}],"container-title":["American Journal of Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.1097\/COC.0000000000001336","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T12:33:41Z","timestamp":1787747621000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.1097\/COC.0000000000001336"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,25]]},"references-count":23,"URL":"https:\/\/doi.org\/10.1097\/coc.0000000000001336","relation":{},"ISSN":["0277-3732","1537-453X"],"issn-type":[{"value":"0277-3732","type":"print"},{"value":"1537-453X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,25]]},"assertion":[{"value":"2026-04-15","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-04-16","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}